Share This Page
Drugs in ATC Class A10BX
✉ Email this page to a colleague
Drugs in ATC Class: A10BX - Other blood glucose lowering drugs, excl. insulins
| Tradename | Generic Name |
|---|---|
| NATEGLINIDE | nateglinide |
| PRANDIMET | metformin hydrochloride; repaglinide |
| PRANDIN | repaglinide |
| REPAGLINIDE | repaglinide |
| REPAGLINIDE AND METFORMIN HYDROCHLORIDE | metformin hydrochloride; repaglinide |
| STARLIX | nateglinide |
| >Tradename | >Generic Name |
Showing 1 to 6 of 6 entries
A10BX Market Analysis and Financial Projection
The ATC class A10BX encompasses a diverse range of non-insulin blood glucose-lowering drugs, including repaglinide, nateglinide, and newer entrants like tirzepatide, imeglimin, and dorzagliatin. These drugs are gaining traction amid rising global diabetes prevalence and evolving treatment paradigms.
Market Overview
The global non-insulin diabetes therapies market, which includes A10BX drugs, was valued at $21.1 billion in 2022 and is projected to reach $32.3 billion by 2030 (CAGR: 5.5%)[4]. Key growth drivers include:
- Increasing diabetes prevalence: Over 37 million Americans had diabetes in 2022, with similar trends globally[4].
- Advancements in combination therapies: Drugs like AC-201 (TWi Biotechnology) enhance efficacy when paired with metformin[3][14].
- Novel mechanisms: Dorzagliatin (a glucokinase activator) and imeglimin (mitochondrial function modulator) address unmet needs[14][15].
| Key A10BX Subclasses | Drug | ATC Code | 2023 Market Size | 2033 Projection | CAGR |
|---|---|---|---|---|---|
| Repaglinide | A10BX02 | $1.5 billion[12] | $2.3 billion[12] | 5.2% | |
| Tirzepatide | A10BX16 | Dominated by Eli Lilly (101 patents)[13] | — | — | |
| Dorzagliatin | A10BX18 | Emerging | $2.3 billion[15] | 6.5% |
Patent Landscape
Recent Innovations and Protections:
- Tirzepatide: Eli Lilly leads with 101 patents, focusing on formulation and combination therapies[13].
- Imeglimin: Poxel secured Chinese patent protection until 2039 for renal-impaired patients, targeting 32 million Chinese diabetics[14].
- SiPore®: Sigrid Therapeutics obtained a US patent (2024) for its glucose-lowering silica particles, highlighting non-pharmacological approaches[8].
- AC-201: TWi Biotechnology’s US patent covers combination therapies with metformin, addressing monotherapy limitations[3].
Strategic Trends:
- Geographic expansion: 46% of A10BX-related patents target Asia-Pacific markets, driven by China’s diabetic population[15][16].
- Generics: Repaglinide’s market grows at 3.6% CAGR (2024–2031) despite generic competition, emphasizing post-patent accessibility[11].
Regional Dynamics
- North America: Holds 38% market share due to strong healthcare infrastructure and high diabetes rates[4].
- Asia-Pacific: Fastest-growing region (CAGR: 7.8%) with Hua Medicine’s dorzagliatin approved in China as a first-in-class GKA drug[15][16].
- Europe: Focus on combination therapies, e.g., nateglinide with thioctic acid (A10BX03)[1].
Competitive Landscape
Leading Players:
- Eli Lilly: Dominates tirzepatide patents; 14% of A10BX pipeline[13].
- Hua Medicine: Commercializing dorzagliatin in China, investing $58 million in production[16].
- Sanofi, Novo Nordisk: Expanding SGLT-2 and GLP-1 portfolios overlapping with A10BX combinations[4][10].
R&D Focus:
- Personalized therapies: Imeglimin targets mitochondrial dysfunction in renal-impaired patients[14].
- Preventive approaches: SiPore® aims to reduce diabetes risk through dietary supplements[8].
Future Outlook
- Regulatory Momentum: 60% of A10BX drugs in Phase III trials target combination therapies (e.g., carfloglitazar)[1][15].
- Market Challenges: Hypoglycemia risks with repaglinide and pricing pressures from alternatives like SGLT-2 inhibitors[12].
- Projections: By 2030, A10BX drugs could capture 25% of the non-insulin market, driven by novel mechanisms and Asia-Pacific adoption[4][15].
"The granting of patents like imeglimin’s in China validates the shift toward addressing diabetes comorbidities." [14].
This evolving landscape underscores the critical role of innovation and strategic IP management in addressing the global diabetes epidemic.
References
- https://atcddd.fhi.no/atc_ddd_index/?code=A10BX&showdescription=yes
- https://patentimages.storage.googleapis.com/1b/86/c7/9ca3f14cef1d4f/US9364519.pdf
- https://www.fiercebiotech.com/biotech/twi-biotechnology-receives-patent-allowance-for-its-lead-drug-candidate-ac-201-united
- https://www.zionmarketresearch.com/report/non-insulin-therapies-for-diabetes-market
- https://en.wikipedia.org/wiki/ATC_code_A10
- https://repub.eur.nl/pub/23488/ERS-2011-010-MKT.pdf
- https://personal.eur.nl/stremersch/artikels/Verniers_Stremersch_Croux_2011_IJRM_Print.pdf
- https://manufacturingchemist.com/sigrid-therapeutics-sipore-blood-glucose-lowering-silica-obtains-us-patent
- https://drc.bmj.com/content/10/6/e002995
- https://www.canada.ca/en/patented-medicine-prices-review/services/npduis/analytical-studies/mir-antidiabetic-drugs-2012-2021.html
- https://www.marketresearchintellect.com/product/global-repaglinide-market-size-and-forcast/
- https://www.verifiedmarketreports.com/product/repaglinide-market/
- https://www.patsnap.com/resources/blog/the-evolution-of-tirzepatides-competitive-landscape/
- https://www.biospace.com/press-releases/poxel-announces-the-grant-of-patent-in-china-protecting-the-use-of-imeglimin-for-type-2-diabetic-patients-with-renal-impairment
- https://datahorizzonresearch.com/dorzagliatin-market-14797
- https://www.huamedicine.com/En/news-231
More… ↓
